CLS Investments LLC held its stake in SPDR S&P Biotech (NYSEARCA:XBI) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 23,000 shares of the exchange traded fund’s stock at the end of the second quarter. CLS Investments LLC’s holdings in SPDR S&P Biotech were worth $1,775,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of XBI. Wechter Feldman Wealth Management Inc. boosted its position in shares of SPDR S&P Biotech by 0.4% in the second quarter. Wechter Feldman Wealth Management Inc. now owns 3,172 shares of the exchange traded fund’s stock worth $245,000 after buying an additional 12 shares during the last quarter. Willingdon Wealth Management boosted its position in shares of SPDR S&P Biotech by 1.8% in the second quarter. Willingdon Wealth Management now owns 6,541 shares of the exchange traded fund’s stock worth $505,000 after buying an additional 118 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of SPDR S&P Biotech by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 19,274 shares of the exchange traded fund’s stock worth $1,488,000 after buying an additional 197 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of SPDR S&P Biotech by 4.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 8,692 shares of the exchange traded fund’s stock worth $671,000 after buying an additional 346 shares during the last quarter. Finally, FineMark National Bank & Trust boosted its position in shares of SPDR S&P Biotech by 7.4% in the second quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock worth $402,000 after buying an additional 360 shares during the last quarter.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) traded down 0.94% on Friday, hitting $77.81. The company had a trading volume of 2,399,585 shares. SPDR S&P Biotech has a 1-year low of $53.15 and a 1-year high of $82.38. The company has a 50 day moving average price of $77.91 and a 200 day moving average price of $72.45. SPDR S&P Biotech also was the target of some unusual options trading on Thursday. Stock traders purchased 27,475 put options on the stock. This is an increase of approximately 160% compared to the typical volume of 10,556 put options.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/27/cls-investments-llc-has-1775000-position-in-spdr-sp-biotech-xbi.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Stock Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related stocks with our FREE daily email newsletter.